Jump Financial LLC Lowers Position in UroGen Pharma Ltd. (NASDAQ:URGN)

Jump Financial LLC lessened its stake in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 69.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,185 shares of the company's stock after selling 39,265 shares during the period. Jump Financial LLC owned approximately 0.07% of UroGen Pharma worth $183,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Barclays PLC increased its holdings in shares of UroGen Pharma by 409.3% in the 3rd quarter. Barclays PLC now owns 59,778 shares of the company's stock worth $759,000 after purchasing an additional 48,040 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of UroGen Pharma by 263.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 68,062 shares of the company's stock worth $864,000 after buying an additional 49,318 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of UroGen Pharma by 8.1% in the 3rd quarter. Geode Capital Management LLC now owns 455,637 shares of the company's stock worth $5,787,000 after buying an additional 34,248 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of UroGen Pharma by 7.3% in the 4th quarter. Bank of New York Mellon Corp now owns 93,997 shares of the company's stock worth $1,001,000 after buying an additional 6,430 shares during the last quarter. Finally, Oppenheimer & Co. Inc. purchased a new position in shares of UroGen Pharma in the 4th quarter worth $126,000. Institutional investors own 91.29% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. LADENBURG THALM/SH SH assumed coverage on UroGen Pharma in a research note on Wednesday, February 19th. They issued a "buy" rating and a $31.00 price target on the stock. The Goldman Sachs Group lowered their target price on UroGen Pharma from $22.00 to $16.00 and set a "neutral" rating on the stock in a research report on Thursday, April 17th. D. Boral Capital reiterated a "buy" rating and set a $25.00 target price on shares of UroGen Pharma in a research report on Monday. Scotiabank started coverage on UroGen Pharma in a research report on Wednesday, April 16th. They set a "sector outperform" rating and a $23.00 target price on the stock. Finally, HC Wainwright reiterated a "buy" rating and set a $55.00 target price on shares of UroGen Pharma in a research report on Monday. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $32.86.

UroGen Pharma Trading Up 14.1 %

Shares of URGN opened at $11.26 on Tuesday. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. UroGen Pharma Ltd. has a 1 year low of $8.94 and a 1 year high of $20.70. The company has a 50 day simple moving average of $10.44 and a two-hundred day simple moving average of $11.08. The firm has a market cap of $519.02 million, a P/E ratio of -3.57 and a beta of 0.80.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last announced its quarterly earnings data on Monday, March 10th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.11). The business had revenue of $24.57 million for the quarter, compared to analyst estimates of $25.25 million. On average, equities analysts expect that UroGen Pharma Ltd. will post -3.12 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Mark Schoenberg sold 4,551 shares of UroGen Pharma stock in a transaction on Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $50,698.14. Following the completion of the sale, the insider now directly owns 145,666 shares in the company, valued at approximately $1,622,719.24. This trade represents a 3.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Jason Drew Smith sold 7,379 shares of UroGen Pharma stock in a transaction on Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $82,202.06. Following the sale, the general counsel now owns 26,468 shares of the company's stock, valued at approximately $294,853.52. This trade represents a 21.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.10% of the company's stock.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.